8 GHP Biotechnology & Lifesciences Awards 2025 Based in San Diego, California, Antharis Therapeutics is a company committed to addressing unmet medical needs of patients worldwide, particularly in oncology, through the power of biotherapeutics. With a focus on precision medicine and an extensive portfolio of targetedoncologyandimmuno-oncology innovations, Antharis has proven itself more than adept when it comes to leveraging cutting-edge technologies that accelerate the development of lifesaving treatments. Antharis was founded on the belief that revolutionary research and scientific breakthroughs should lead to demonstrable medical advancements that transform lives. Founded by visionary entrepreneur Dr. Raphael R. Pinaud, who serves as the company’s CEO & Chairman, Antharis is built on a foundation of innovation, expertise, and a commitment to reshaping cancer treatment. At the core of the company is a multidisciplinary team of experts in fields such as molecular and cellular biology, immunology, chemistry and translational medicine, all of whom push the very boundaries of therapeutic innovation. The results of their efforts are opening new frontiers in drug development, advancing the potential for life-changing treatments. Antharis collaborates with a select group of partners to serve a diverse client base, ranging from emerging biotechnology companies aiming to establish themselves, to multinational pharmaceutical companies looking to diversify their asset portfolios by investing in innovative new products. Since its inception, Dr. Pinaud has guided Antharis Therapeutics with his wealth of experience across science, finance and business arenas, playing an essential role in the company’s success at every stage. His strategic vision, creativity, and multidisciplinary approach have positioned Antharis as a top emerging biotech company, setting it apart within the industry and driving breakthrough innovations in oncology and immuno-oncology. Committed to advancing cutting-edge science, Dr. Pinaud has assembled a team of exceptional talent - individuals who are not only among the best in the industry but also invested stakeholders in Antharis, giving them a deep sense of responsibility in shaping its success. This has fostered a culture rooted in collaboration, intellectual rigor, and alignment, which has been invaluable in driving high-quality decisions across the company’s cancer treatment programmes. Highlighting recent projects led by Antharis, Dr. Pinaud shares the exciting progress made through the company’s lead immunooncology and antibody-drug conjugate programmes - both of which have shown promising pre-clinical results in targeting treatment-resistant tumors across various cancer types. As Dr. Pinaud explained: “These novel therapeutic approaches have the potential to fundamentally redefine treatment paradigms in oncology.” Supporting this, Antharis’ advanced pipeline is driven by a steady stream of biotherapy solutions specifically designed to target solid tumours. By developing treatments for a wide range of cancers, the company is making significant strides toward a future where the complexities of tumour biology are not only understood but effectively addressed. In the long term, this will lead to the widespread deployment of therapeutic solutions across various cancer types, offering the potential to save countless lives. In addition to its treatments, Antharis is evolving into a clinicalstage company, with plans to advance three of its lead assets into clinical trials this year. This major milestone underscores the company’s commitment to delivering high-impact therapies for conditions with limited treatment options. Dr. Pinaud explained: “These assets have demonstrated exceptional therapeutic potential in pre-clinical studies, and we are excited to move them into the clinic with the ultimate goal of helping patients across various cancer types.” Having secured these launches, Antharis is also focused on expanding and advancing its pipeline, with plans to bring more products into clinical development. Multiple assets are currently in progress, and the company is leveraging biomarkerdriven approaches and AI to streamline efforts, reduce development timelines, and increase success rates. To ensure continued progress, Dr. Pinaud and the team are strengthening collaborations with strategic partners while also investing in internal training and growth. “In summary, we are at a pivotal moment in our journey, and 2025 marks a transformative year as we officially transition to a clinical-stage company,” says Dr. Pinaud in closing. “Antharis is not merely entering the clinic - we are doing so with a robust pipeline of assets positioned for success. Supported by cuttingedge science, a strategic vision, and a world-class team, we are moving forward with the goal of making a real impact for patients and shaping the future of medicine.” We wish Dr. Raphael R. Pinaud and the entire team the best of luck in pursuing their overarching vision, celebrating their impressive success in biotherapeutics so far with these two well-deserved awards. Contact Details Contact: Dr. Raphael R. Pinaud Company: Antharis Therapeutics Web Address: https://www.antharistherapeutics.com/ Most Pioneering Biopharmaceutical Company of 2025 – USA & GHP Innovation Excellence Award of Year 2025 AntharisTherapeutics
RkJQdWJsaXNoZXIy NTY1MjM3